200 related articles for article (PubMed ID: 30871240)
1. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models.
Gravina GL; Mancini A; Colapietro A; Delle Monache S; Sferra R; Vitale F; Cristiano L; Martellucci S; Marampon F; Mattei V; Beirinckx F; Pujuguet P; Saniere L; Lorenzon G; van der Aar E; Festuccia C
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871240
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
[TBL] [Abstract][Full Text] [Related]
3. Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines
Colapietro A; Gravina GL; Petragnano F; Fasciani I; Scicchitano BM; Beirinckx F; Pujuguet P; Saniere L; Van der Aar E; Musio D; De Felice F; Mattei V; Martellucci S; Maggio R; Tombolini V; Festuccia C; Marampon F
J Oncol; 2020; 2020():9342732. PubMed ID: 32184826
[TBL] [Abstract][Full Text] [Related]
4. Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma.
Colapietro A; Mancini A; Vitale F; Martellucci S; Angelucci A; Llorens S; Mattei V; Gravina GL; Alonso GL; Festuccia C
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936544
[TBL] [Abstract][Full Text] [Related]
5. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA; Vora P; Venugopal C; Adams J; Singh M; Hu A; Gorelik M; Subapanditha MK; Savage N; Yang J; Chokshi C; London M; Gont A; Bobrowski D; Grinshtein N; Brown KR; Murty NK; Nilvebrant J; Kaplan D; Moffat J; Sidhu S; Singh SK
Cancer Res; 2018 Sep; 78(17):5023-5037. PubMed ID: 29945963
[TBL] [Abstract][Full Text] [Related]
7. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
8. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
9. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice.
Festuccia C; Gravina GL; Giorgio C; Mancini A; Pellegrini C; Colapietro A; Delle Monache S; Maturo MG; Sferra R; Chiodelli P; Rusnati M; Cantoni A; Castelli R; Vacondio F; Lodola A; Tognolini M
Oncotarget; 2018 May; 9(36):24347-24363. PubMed ID: 29849945
[TBL] [Abstract][Full Text] [Related]
10. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma.
Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S
Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
12. CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma.
Wang SM; Lin WC; Lin HY; Chen YL; Ko CY; Wang JM
Cell Death Discov; 2021 Jan; 7(1):8. PubMed ID: 33436575
[TBL] [Abstract][Full Text] [Related]
13. Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
Colapietro A; Rossetti A; Mancini A; Martellucci S; Ocone G; Pulcini F; Biordi L; Cristiano L; Mattei V; Delle Monache S; Marampon F; Gravina GL; Festuccia C
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832864
[TBL] [Abstract][Full Text] [Related]
14. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
15. A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis.
Wen YT; Wu AT; Bamodu OA; Wei L; Lin CM; Yen Y; Chao TY; Mukhopadhyay D; Hsiao M; Huang HS
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561595
[TBL] [Abstract][Full Text] [Related]
16. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
17. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Eom KY; Cho BJ; Choi EJ; Kim JH; Chie EK; Wu HG; Kim IH; Paek SH; Kim JS; Kim IA
Cancer Res Treat; 2016 Apr; 48(2):687-97. PubMed ID: 26044161
[TBL] [Abstract][Full Text] [Related]
19. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
20. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo.
Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A
Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
